Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Last year, the FDA approved three new antibody-drug conjugates for treating cancer.
Genitourinary Cancers Symposium reaches beyond the latest prostate, bladder and kidney cancer treatments.
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.
Here’s a list of the approved drugs to treat bladder cancer. Click on any of the medications for more info on indications, dosing and...
An anthrax-based treatment holds promise against this difficult-to-treat malignancy.
Those with bladder, larynx, prostate, womb, bowel and breast cancers have the highest rate of death related to cardiovascular disease.
A consortium of health providers and researchers hopes to raise public awareness of how exercise can benefit those living with cancer.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
The cancer is particularly difficult to treat with traditional therapies.
New results confirm that the drug, Balversa (erdafitinib), can benefit people whose tumors have a certain genetic alteration.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.